Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2012

01-06-2012 | Clinical Trial

Which prediction models best identify additional axillary disease after a positive sentinel node biopsy for breast cancer?

Authors: Tanya S. Berrang, Mary Lesperance, Pauline T. Truong, Caroline Walter, Allen H. Hayashi, Ivo A. Olivotto

Published in: Breast Cancer Research and Treatment | Issue 2/2012

Login to get access

Abstract

To determine which web-based model best identifies women at low risk of further axillary disease after a positive sentinel lymph node (SLN+) biopsy. 673 women with T1-2cN0M0 SNB+ breast cancer who underwent completion axillary dissection (AxD) were identified. A subgroup not eligible to avoid AxD as part of the Z0011 study was defined (Z0011 exclusion group). Predicted risk of further axillary disease was generated using seven web-based models. “Low risk” was defined as a ≤10% risk of further axillary disease. False negative (“low risk” prediction but AxD+) rates (FNRs), area under the receiver operating characteristic curve (AUC), and Brier score were determined for each model. 6 of 7 models identified “low risk” patients but FNRs ranged from 14 to 30%. The Stanford and Memorial Sloan-Kettering (MSKCC) models had the best FNRs. FNRs were lower with SLN micrometastasis (7–15%) and higher in the Z0011 exclusion group (21–41%). All models under-predicted further nodal disease in low risk patients and over-predicted in higher-risk patients. The Stanford and MSKCC models were able to identify women with SLN micrometastasis with a ≤10% FNR. Models were not able to accurately identify low risk women from a cohort that would have been excluded from Z0011.
Literature
1.
go back to reference Giuliano AE, Jones RC, Brennan M et al (1997) Sentinel lymphadenectomy in breast cancer. J Clin Oncol 15:2345–2350PubMed Giuliano AE, Jones RC, Brennan M et al (1997) Sentinel lymphadenectomy in breast cancer. J Clin Oncol 15:2345–2350PubMed
2.
go back to reference Lyman GH, Giuliano AE, Somerfield MR et al (2005) American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 23:7703–7720PubMedCrossRef Lyman GH, Giuliano AE, Somerfield MR et al (2005) American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 23:7703–7720PubMedCrossRef
3.
go back to reference Rubio IT, Korourian S, Cowan C et al (1998) Sentinel lymph node biopsy for staging breast cancer. Am J Surg 176:532–537PubMedCrossRef Rubio IT, Korourian S, Cowan C et al (1998) Sentinel lymph node biopsy for staging breast cancer. Am J Surg 176:532–537PubMedCrossRef
4.
go back to reference Veronesi U, Paganelli G, Galimberti V et al (1997) Sentinel node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 349:1864–1867PubMedCrossRef Veronesi U, Paganelli G, Galimberti V et al (1997) Sentinel node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 349:1864–1867PubMedCrossRef
5.
go back to reference Krag DN, Anderson SJ, Julian TB et al (2010) Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomized phase 3 trial. Lancet Oncol 11:927–933PubMedCrossRef Krag DN, Anderson SJ, Julian TB et al (2010) Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomized phase 3 trial. Lancet Oncol 11:927–933PubMedCrossRef
6.
go back to reference Kamath VJ, Giuliano R, Dauway EL et al (2001) Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla. Arch Surg 136:688–692PubMedCrossRef Kamath VJ, Giuliano R, Dauway EL et al (2001) Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla. Arch Surg 136:688–692PubMedCrossRef
7.
go back to reference Erb KM, Julian TB (2009) Completion of axillary dissection for a positive sentinel node: necessary or not? Curr Oncol Rep 11:15–20PubMedCrossRef Erb KM, Julian TB (2009) Completion of axillary dissection for a positive sentinel node: necessary or not? Curr Oncol Rep 11:15–20PubMedCrossRef
8.
go back to reference Cantin J, Scarth H, Levine M et al (2001) Clinical practice guidelines for the care and treatment of breast cancer: 13. Sentinel lymph node biopsy. CMAJ 165:166–173PubMed Cantin J, Scarth H, Levine M et al (2001) Clinical practice guidelines for the care and treatment of breast cancer: 13. Sentinel lymph node biopsy. CMAJ 165:166–173PubMed
9.
go back to reference Giuliano AE, McCall LM, Beitsch PD et al (2010) ACOSOG Z0011: a randomized trial of axillary node dissection in women with clinical T1–2 N0 M0 breast cancer who have a positive sentinel node. J Clin Oncol 18s:28s (suppl; abstr CRA506) Giuliano AE, McCall LM, Beitsch PD et al (2010) ACOSOG Z0011: a randomized trial of axillary node dissection in women with clinical T1–2 N0 M0 breast cancer who have a positive sentinel node. J Clin Oncol 18s:28s (suppl; abstr CRA506)
10.
go back to reference Chu KU, Turner RR, Hansen NM et al (1999) Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann Surg 229:536–541PubMedCrossRef Chu KU, Turner RR, Hansen NM et al (1999) Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann Surg 229:536–541PubMedCrossRef
11.
go back to reference Turner RR, Chu KU, Qi K et al (2000) Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer 89:574–581PubMedCrossRef Turner RR, Chu KU, Qi K et al (2000) Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer 89:574–581PubMedCrossRef
12.
go back to reference Giuliano AE, Kirgan DM, Guenther JM et al (1994) Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 220:391–401PubMedCrossRef Giuliano AE, Kirgan DM, Guenther JM et al (1994) Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 220:391–401PubMedCrossRef
13.
go back to reference Fisher B, Jeong JH, Anderson S et al (2002) Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Eng J Med 347:567–575CrossRef Fisher B, Jeong JH, Anderson S et al (2002) Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Eng J Med 347:567–575CrossRef
14.
go back to reference Guenther JM, Hansen NM, DiFronzo LA et al (2003) Axillary dissection is not required for all patients with breast cancer and positive nodes. Arch Surg 138:52–56PubMedCrossRef Guenther JM, Hansen NM, DiFronzo LA et al (2003) Axillary dissection is not required for all patients with breast cancer and positive nodes. Arch Surg 138:52–56PubMedCrossRef
15.
go back to reference Giuliano AE, Hunt KK, Ballman KV et al (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. AMA 305:569–575CrossRef Giuliano AE, Hunt KK, Ballman KV et al (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. AMA 305:569–575CrossRef
16.
go back to reference Galper S, Recht A, Silver B et al (2000) Is radiation alone adequate treatment to the axilla for patients with limited axillary surgery? Implications for treatment after a positive sentinel node biopsy. Int J Radiat Oncol Biol Phys 48:125–132PubMedCrossRef Galper S, Recht A, Silver B et al (2000) Is radiation alone adequate treatment to the axilla for patients with limited axillary surgery? Implications for treatment after a positive sentinel node biopsy. Int J Radiat Oncol Biol Phys 48:125–132PubMedCrossRef
17.
go back to reference Takeda A, Sigematsu N, Kondo M et al (2001) Radiotherapy after breast-conserving surgery without axillary dissection for T1–2, no breast cancer patients: comparison of the tangential and three-field irradiation technique. Int J Radiat Oncol Biol Phys 51(3):S243 (suppl 1)CrossRef Takeda A, Sigematsu N, Kondo M et al (2001) Radiotherapy after breast-conserving surgery without axillary dissection for T1–2, no breast cancer patients: comparison of the tangential and three-field irradiation technique. Int J Radiat Oncol Biol Phys 51(3):S243 (suppl 1)CrossRef
18.
go back to reference Rutgers EJ, Meijnen P, Bonnefoi H (2004) Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group. Breast Cancer Res 6:165–169PubMedCrossRef Rutgers EJ, Meijnen P, Bonnefoi H (2004) Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group. Breast Cancer Res 6:165–169PubMedCrossRef
19.
go back to reference Straver ME, Meijnen P, Van Tienhoven G et al (2010) Sentinel node identification rate and nodal involvement in the EORTC 10981–22023 AMAROS trial. Ann Surg Oncol 17:1854–1861PubMedCrossRef Straver ME, Meijnen P, Van Tienhoven G et al (2010) Sentinel node identification rate and nodal involvement in the EORTC 10981–22023 AMAROS trial. Ann Surg Oncol 17:1854–1861PubMedCrossRef
20.
go back to reference Rietman JS, Geertzen JH, Hoekstra HJ et al (2006) Long term treatment related upper limb morbidity and quality of life after sentinel lymph node biopsy for stage I or II breast cancer. Eur J Surg Oncol 32:148–152PubMedCrossRef Rietman JS, Geertzen JH, Hoekstra HJ et al (2006) Long term treatment related upper limb morbidity and quality of life after sentinel lymph node biopsy for stage I or II breast cancer. Eur J Surg Oncol 32:148–152PubMedCrossRef
21.
go back to reference Mamounas EP (2003) NSABP breast cancer clinical trials: recent results and future directions. Clin Med Res 1:309–326PubMedCrossRef Mamounas EP (2003) NSABP breast cancer clinical trials: recent results and future directions. Clin Med Res 1:309–326PubMedCrossRef
22.
go back to reference Veronesi U, Paganelli G, Viale G et al (2003) A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349:546–553PubMedCrossRef Veronesi U, Paganelli G, Viale G et al (2003) A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349:546–553PubMedCrossRef
23.
go back to reference Rietman JS, Dijkstra PU, Geertzen JH et al (2003) Short-term morbidity of the upper limb after sentinel lymph node biopsy or axillary lymph node dissection for Stage I or II breast carcinoma. Cancer 98:690–696PubMedCrossRef Rietman JS, Dijkstra PU, Geertzen JH et al (2003) Short-term morbidity of the upper limb after sentinel lymph node biopsy or axillary lymph node dissection for Stage I or II breast carcinoma. Cancer 98:690–696PubMedCrossRef
24.
go back to reference Mansel RE, Fallowfield L, Kissin M et al (2006) Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 98:599–609PubMedCrossRef Mansel RE, Fallowfield L, Kissin M et al (2006) Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 98:599–609PubMedCrossRef
25.
go back to reference Van Zee KJ, Manasseh DM, Bevilacqua JL et al (2003) A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 10:1140–1151PubMedCrossRef Van Zee KJ, Manasseh DM, Bevilacqua JL et al (2003) A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 10:1140–1151PubMedCrossRef
26.
go back to reference Kohrt HE, Olshen RA, Bermas HR et al (2008) New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer 8:66PubMedCrossRef Kohrt HE, Olshen RA, Bermas HR et al (2008) New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer 8:66PubMedCrossRef
27.
go back to reference Barranger E, Coutant C, Flahault A et al (2005) An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement. Breast Cancer Res Treat 91:113–119PubMedCrossRef Barranger E, Coutant C, Flahault A et al (2005) An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement. Breast Cancer Res Treat 91:113–119PubMedCrossRef
28.
go back to reference Pal A, Provenzano E, Duffy SW et al (2008) A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive. Br J Surg 95:302–309PubMedCrossRef Pal A, Provenzano E, Duffy SW et al (2008) A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive. Br J Surg 95:302–309PubMedCrossRef
29.
go back to reference Degnim AC, Reynolds C, Pantvaidya G et al (2005) Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram. Am J Surg 190:543–550PubMedCrossRef Degnim AC, Reynolds C, Pantvaidya G et al (2005) Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram. Am J Surg 190:543–550PubMedCrossRef
30.
go back to reference Katz A, Smith BL, Golshan M et al (2008) Nomogram for the prediction of having four or more involved nodes for sentinel lymph node—positive breast cancer. J Clin Oncol 26:2093–2098PubMedCrossRef Katz A, Smith BL, Golshan M et al (2008) Nomogram for the prediction of having four or more involved nodes for sentinel lymph node—positive breast cancer. J Clin Oncol 26:2093–2098PubMedCrossRef
31.
go back to reference Unal B, Gur AS, Kayiran O et al (2008) Models for predicting non-sentinel lymph node positivity in sentinel node positive breast cancer: the importance of scoring system. Int J Clin Pract 62:1785–1791PubMedCrossRef Unal B, Gur AS, Kayiran O et al (2008) Models for predicting non-sentinel lymph node positivity in sentinel node positive breast cancer: the importance of scoring system. Int J Clin Pract 62:1785–1791PubMedCrossRef
32.
go back to reference Dauphine CE, Haukoos JS, Vargas MP et al (2007) Evaluation of three scoring systems predicting non sentinel node metastasis in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 14:1014–1019PubMedCrossRef Dauphine CE, Haukoos JS, Vargas MP et al (2007) Evaluation of three scoring systems predicting non sentinel node metastasis in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 14:1014–1019PubMedCrossRef
33.
go back to reference Cripe MH, Beran LC, Liang WC et al (2006) The likelihood of additional nodal disease following a positive sentinel lymph node biopsy in breast cancer patients: validation of a nomogram. Am J Surg 192:484–487PubMedCrossRef Cripe MH, Beran LC, Liang WC et al (2006) The likelihood of additional nodal disease following a positive sentinel lymph node biopsy in breast cancer patients: validation of a nomogram. Am J Surg 192:484–487PubMedCrossRef
34.
go back to reference Kocsis L, Svebis M, Boross G et al (2004) Use and limitations of a nomogram predicting the likelihood of non-sentinel node involvement after a positive sentinel node biopsy in breast cancer patients. Am Surg 70:1019–1024PubMed Kocsis L, Svebis M, Boross G et al (2004) Use and limitations of a nomogram predicting the likelihood of non-sentinel node involvement after a positive sentinel node biopsy in breast cancer patients. Am Surg 70:1019–1024PubMed
35.
go back to reference Lambert LA, Ayers GD, Hwang RF et al (2006) Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy. Ann Surg Oncol 13:310–320PubMedCrossRef Lambert LA, Ayers GD, Hwang RF et al (2006) Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy. Ann Surg Oncol 13:310–320PubMedCrossRef
36.
go back to reference Smidt ML, Kuster DM, van der Wilt GJ et al (2005) Can the Memorial Sloan-Kettering Cancer Center nomogram predict the likelihood of nonsentinel lymph node metastases in breast cancer patients in the Netherlands? Ann Surg Oncol 12:1066–1072PubMedCrossRef Smidt ML, Kuster DM, van der Wilt GJ et al (2005) Can the Memorial Sloan-Kettering Cancer Center nomogram predict the likelihood of nonsentinel lymph node metastases in breast cancer patients in the Netherlands? Ann Surg Oncol 12:1066–1072PubMedCrossRef
37.
go back to reference Zgajnar J, Perhavec A, Hocevar M et al (2007) Low performance of the MSKCC nomogram in preoperatively ultrasonically negative axillary lymph node in breast cancer patients. J Surg Oncol 96:547–553PubMedCrossRef Zgajnar J, Perhavec A, Hocevar M et al (2007) Low performance of the MSKCC nomogram in preoperatively ultrasonically negative axillary lymph node in breast cancer patients. J Surg Oncol 96:547–553PubMedCrossRef
38.
go back to reference Alran S, De Rycke Y, Fourchotte V et al (2007) Validation and limitations of use of a breast cancer nomogram predicting the likelihood of non-sentinel node involvement after positive sentinel node biopsy. Ann Surg Oncol 14:2195–2201PubMedCrossRef Alran S, De Rycke Y, Fourchotte V et al (2007) Validation and limitations of use of a breast cancer nomogram predicting the likelihood of non-sentinel node involvement after positive sentinel node biopsy. Ann Surg Oncol 14:2195–2201PubMedCrossRef
39.
go back to reference Coutant C, Olivier C, Lambaudie E et al (2009) Comparison of models to predict non-sentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: a prospective multicenter study. J Clin Oncol 27(17):2800–2808PubMedCrossRef Coutant C, Olivier C, Lambaudie E et al (2009) Comparison of models to predict non-sentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: a prospective multicenter study. J Clin Oncol 27(17):2800–2808PubMedCrossRef
40.
go back to reference Parra RFD, Ernst MF, Bevilacqua JLB et al (2009) Validation of a nomogram to predict the risk of non-sentinel lymph node metastases in breast cancer patients with a positive sentinel node biopsy: validation of the MSKCC breast nomogram. Ann Surg Oncol 16:1128–1135CrossRef Parra RFD, Ernst MF, Bevilacqua JLB et al (2009) Validation of a nomogram to predict the risk of non-sentinel lymph node metastases in breast cancer patients with a positive sentinel node biopsy: validation of the MSKCC breast nomogram. Ann Surg Oncol 16:1128–1135CrossRef
42.
go back to reference Harrell F (2001) Regression modeling strategies. Springer, New York Harrell F (2001) Regression modeling strategies. Springer, New York
43.
go back to reference Krag DN, Anderson SJ, Julian TB et al (2007) Technical outcomes of sentinel-lymph node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomized phase III trial. Lancet Oncol 8:881–888PubMedCrossRef Krag DN, Anderson SJ, Julian TB et al (2007) Technical outcomes of sentinel-lymph node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomized phase III trial. Lancet Oncol 8:881–888PubMedCrossRef
44.
go back to reference Tafra L, McMasters K, Whitworth P et al (2000) Credentialing issues with sentinel lymph node staging for breast cancer. Am J Surg 180(4):268–273PubMedCrossRef Tafra L, McMasters K, Whitworth P et al (2000) Credentialing issues with sentinel lymph node staging for breast cancer. Am J Surg 180(4):268–273PubMedCrossRef
45.
47.
go back to reference Caudle AS, Hunt KK, Kuerer HM et al (2011) Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol 9(18):2407–2412CrossRef Caudle AS, Hunt KK, Kuerer HM et al (2011) Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol 9(18):2407–2412CrossRef
48.
go back to reference Carlson GW, Wood WC (2011) Management of axillary lymph node metastasis in breast cancer: making progress. JAMA 305(6):606–607PubMedCrossRef Carlson GW, Wood WC (2011) Management of axillary lymph node metastasis in breast cancer: making progress. JAMA 305(6):606–607PubMedCrossRef
Metadata
Title
Which prediction models best identify additional axillary disease after a positive sentinel node biopsy for breast cancer?
Authors
Tanya S. Berrang
Mary Lesperance
Pauline T. Truong
Caroline Walter
Allen H. Hayashi
Ivo A. Olivotto
Publication date
01-06-2012
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-012-1991-y

Other articles of this Issue 2/2012

Breast Cancer Research and Treatment 2/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine